These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 19849819)

  • 1. Progress in osteoporosis and fracture prevention: focus on postmenopausal women.
    Saag KG; Geusens P
    Arthritis Res Ther; 2009; 11(5):251. PubMed ID: 19849819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.
    Miller RG
    Geriatrics; 2006 Jan; 61(1):24-30. PubMed ID: 16405361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
    Reginster JY
    Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current approach to fracture prevention in postmenopausal osteoporosis.
    Kaplan B; Hirsch M
    Clin Exp Obstet Gynecol; 2004; 31(4):251-5. PubMed ID: 15672957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of postmenopausal osteoporosis pharmacotherapy.
    Mayes SL
    Nutr Clin Pract; 2007 Jun; 22(3):276-85. PubMed ID: 17507728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis.
    Delmas PD
    Bone; 2002 Jan; 30(1):14-7. PubMed ID: 11792559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing osteoporosis-related fractures: an overview.
    Gass M; Dawson-Hughes B
    Am J Med; 2006 Apr; 119(4 Suppl 1):S3-S11. PubMed ID: 16563939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporosis and fracture risk in older people.
    Coughlan T; Dockery F
    Clin Med (Lond); 2014 Apr; 14(2):187-91. PubMed ID: 24715132
    [No Abstract]   [Full Text] [Related]  

  • 11. Risedronate for the prevention of fractures in postmenopausal osteoporosis.
    Sickels JM; Nip CS
    Ann Pharmacother; 2002 Apr; 36(4):664-70. PubMed ID: 11918518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for treatment to prevent fragility fractures in postmenopausal women.
    Geusens P
    Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):727-40. PubMed ID: 19945685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
    Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recognition of women at risk for fracture and intervention with fast-acting therapies.
    Derman R
    Int J Fertil Womens Med; 2006; 51(4):183-90. PubMed ID: 17184104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO).
    Silva BC; Madeira M; d'Alva CB; Maeda SS; de Holanda NCP; Ohe MN; Szejnfeld V; Zerbini CAF; de Paula FJA; Bandeira F
    Arch Endocrinol Metab; 2022 Nov; 66(5):591-603. PubMed ID: 36191263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.
    Siris ES; Baim S; Nattiv A
    Postgrad Med; 2010 Jan; 122(1):82-90. PubMed ID: 20107292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.
    Kanis JA; McCloskey EV; Johansson H; Strom O; Borgstrom F; Oden A;
    Osteoporos Int; 2008 Oct; 19(10):1395-408. PubMed ID: 18751937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.
    Qaseem A; Forciea MA; McLean RM; Denberg TD; ; Barry MJ; Cooke M; Fitterman N; Harris RP; Humphrey LL; Kansagara D; McLean RM; Mir TP; Schünemann HJ
    Ann Intern Med; 2017 Jun; 166(11):818-839. PubMed ID: 28492856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.